Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies

  • Authors:
    • Semir Vranic
    • Zoran Gatalica
    • Zhao-Yi Wang
  • View Affiliations

  • Published online on: August 5, 2011     https://doi.org/10.3892/ol.2011.375
  • Pages: 1131-1137
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Apocrine carcinoma of the breast has recently been refined through gene expression profiling. Due to various pathological studies, we compared the results with the MDA-MB-453 breast cancer cell line, a proposed model for apocrine breast carcinoma. The MDA-MB-453 cell line is androgen receptor-positive and ‘triple-negative’ in respect to estrogen receptor-α, progesterone receptor and the Her-2/neu protein expression. Cytogenetic analysis of the cell line revealed a hypertriploid clone characterized by extensive numerical and structural abnormalities including loss of the 9p.21 locus (P16-INK4a gene), also evidenced by the lack of p16INK4A protein expression in Western blot analysis and immunocytochemistry assays. Gains of chromosomes 7 and 17 without underlying EGFR, HER-2/neu, and TOP2A gene amplification were also observed. A mutation in the K-RAS gene (Gly13Asp GGC>GAC) was identified in the cell line, which was not observed in the six patient samples of apocrine breast carcinomas examined. Similarly, constitutive activation of the MAPK/ERK signaling pathway and deregulation of cell cycle proteins (p16-/pRb-/cyclin D1+ phenotype) with exceedingly high proliferation observed in the MDA-MB-453 cell line were not found in the tissue samples. In conclusion, the MDA-MB-453 cell line shares certain features with apocrine breast carcinoma but differs from patient tissues with regard to various significant characteristics, limiting the value of this cell line as a model for human apocrine breast carcinoma investigations. In contrast to the cell line, EGFR-positive apocrine carcinomas do not harbor K-RAS gene mutations, rendering these tumors amenable to targeted therapy with EGFR inhibitors.
View Figures
View References

Related Articles

Journal Cover

November-December 2011
Volume 2 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Vranic S, Gatalica Z and Wang Z: Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncol Lett 2: 1131-1137, 2011.
APA
Vranic, S., Gatalica, Z., & Wang, Z. (2011). Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. Oncology Letters, 2, 1131-1137. https://doi.org/10.3892/ol.2011.375
MLA
Vranic, S., Gatalica, Z., Wang, Z."Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies". Oncology Letters 2.6 (2011): 1131-1137.
Chicago
Vranic, S., Gatalica, Z., Wang, Z."Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies". Oncology Letters 2, no. 6 (2011): 1131-1137. https://doi.org/10.3892/ol.2011.375